We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

3 High-Yield Dividend Stocks For The Next Bear Market: GlaxoSmithKline plc, Pearson plc And G4S plc

Should you buy shares in GlaxoSmithKline plc (LON:GSK), Pearson plc (LON:PSON) & G4S plc (LON:GFS) for their dividends?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

When stock markets go awry, high yield stocks tend to outperform the broader market. The high-yielding dividend stocks that perform best in a downturn are so-called defensive ones. These are stocks in companies that provide goods and services always needed throughout the business cycle, enabling them to generate stable profits year after year.

Here are three high-yield stocks that could protect your portfolio in a bear market.

XXX

Controversial

GlaxoSmithKline (LSE: GSK) may be a controversial pick given its poor earnings trend. But as healthcare needs are continually rising, GSK remains a big growth opportunity. And despite recent weak results, it maintains a strong competitive position and has robust free cash flow generation.

Early signs of recovery are also beginning to show, with quarterly sales figures highlighting strong growth from its new pharmaceutical products, especially its new respiratory drug line-up including recently launched Breo, Anoro and Incruse. New products account for just £2bn in annual sales, but with continued sales growth and additional launches, sales could rise to £6bn by 2018.

Meanwhile, investors are being handsomely rewarded for their patience, with shares in the pharma giant currently yielding 5.5%. There’s one major short-term negative: with the dividend being frozen at 80p per share for 2016 and 2017, there’s no dividend growth for at least two years.

Transition

Pearson (LSE: PSON) is going through a rough patch, reporting a 2% drop in adjusted operating profits in 2015 and management giving a weak set of guidance figures for 2016. Adjusted operating profits are expected to come between £580m and £620m in 2016, which at the mid-point implies a decline of 13% on the previous year.

There are causes for optimism though. Pearson‘s competitive position is strong, and cyclical and policy factors are mainly to blame for recent weakness. This included a buoyant employment market in the US, which meant reduced college enrolment, and policy changes in the UK that lowered demand for its vocational course services.

The outlook in the longer term remains attractive. Pearson has significant exposure to growing markets in Brazil, China, India and South Africa, where it’s launching new products such as the New Student Experience. Its transition from print to digital would also likely be positive to its competitive position, given the advantage scale has on digital platforms.

With an annual dividend of 52p per share, Pearson yields 6%.

Market leader

Investor confidence in G4S (LSE: GFS) is near an all-time low, with the company seemingly embroiled in an endless list of controversies, ranging from overcharging of government contracts, human rights violations and abuse at a young offenders centre. But the company is still set to deliver strong underlying growth in revenues and earnings.

G4S remains global market leader in security services and against the backdrop of global economic uncertainty, demand for its services remains robust. In 2015, it secured new contract sales worth £2.4bn with retention rates near 90%. This shows the company has little trouble in winning new contracts even after recent scandals.

City analysts expect underlying EPS will grow 5.6% this year, to 15.2p per share. For 2017, earnings should climb another 9%, to 16.6p. This would put the shares on an attractive forward P/E of 12.2 and 11.2, respectively.

The stock’s 5.1% yield isn’t as big, but there’s potential for faster future dividend growth, given that earnings growth is set to accelerate.

Jack Tang has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Friends and sisters exploring the outdoors together in Cornwall. They are standing with their arms around each other at the coast.
Investing Articles

£503 buys 14 shares in this FTSE 250 stock that returned 23.9% annually for the last 15 years

This FTSE 250 stock has averaged a huge return for 15 years. At today's price, £503 buys 14 shares. But…

Read more »

Black woman using loudspeaker to be heard
Investing Articles

£1,000 buys 25 shares in this FTSE 100 stock that’s returned 29.2% annually for the last 10 years

This FTSE 100 mining stock has returned close to 30% a year for a decade. At 3,995p, £1,000 buys 25…

Read more »

Female student sitting at the steps and using laptop
Investing Articles

Down 47%, is this growth stock finally worth buying in May?

With a £288m order book and a hidden pipeline of defence and nuclear contracts, is this growth stock now too…

Read more »

House models and one with REIT - standing for real estate investment trust - written on it.
Investing Articles

2 REITs yielding 7%+ to consider for passive income in 2026

A REIT backed by the NHS and another backed by Tesco and Sainsbury's with both yielding 7%+. Here's why I'm…

Read more »

Woman riding her old fashioned bicycle along the Beach Esplanade at Aberdeen, Scotland.
Investing Articles

Just 97 shares of this UK dividend stock generate £238 in passive income

A 5.7% yield, £238 in passive income from just 97 shares, and one of the most divisive dividend stocks on…

Read more »

ISA coins
Investing Articles

£10,000 in an ISA generates a second income of…

The London Stock Exchange is home to some of the world's most generous dividends. But how big a second income…

Read more »

Shot of a senior man drinking coffee and looking thoughtfully out of a window
Investing Articles

Expert recommendations: 2 top income stocks yielding 7%+!

With yields of 7.2% and 7.8% respectively, these two income stocks are catching the eyes of institutional analysts. Should investors…

Read more »

Illustration of flames over a black background
Investing Articles

3 top income-focused stocks to buy in May 2026, according to experts

Looking for a stock to buy for income in May 2026? Experts have flagged these three UK dividend shares as…

Read more »